Endocrine Abstracts

Different interdependences with symptoms of insulin resistance give us the possibility to consider steatosis as a disorder of the liver with metabolic syndrome (MS).

The aim of study is to assess the role cholesterol-HDL in rise of diabetic steatohepatosis.

40 patients with Diabetes Mellitus type 2 (DM) and signs of MS were examined to determine spreading of steatohepatosis as one of the factors of insulin resistance. Only 8 of them didn’t have diabetic hepatopathy, while 32 patients had adipose infiltration of the liver (according to the results of the ultrasonic examination).

Actual difference between the two groups was revealed in the rate of HDL decrease. So, if the patients with DM type 2 and symptoms of MS with steatohepatosis have the rate of cholesterol-HDL decrease which is 34.36±4.2% from the low norm measure, the patients with the same symptoms, but without steatohepatosis, had 6.8±0.2% (P<0.05). We distinguished a group of patients who had prevalent fasting hyperglycemia. Those patients who had prelevant postprandian hyperglycemia formed the group of comparison. Analyzing the findings, it is necessary to mention that the group of patients with prevalent fasting hyperglycemia were effected by more serious disorders with lipid metabolism, they had a lower level of cholesterol-HDL than those who had rather high postprandian hyperglycemia (0.89±0.03 vs 1.027±0.05 mmol/l, P<0.05) and rather high percentage of a waste circle growing that indicates of a greater aggressiveness of MS factors.

Thus, it was determined that prevalent fasting hyperglycemia which effects patients with DM type 2 and diabetic hepatopathy in condition of adipose infiltration confirmed by echographic results is a proof of a major role of the liver in the infringement of lipid metabolism that contributes to increasing of insulin resistance due to, so called, ‘lipid toxity’.